Merck Regains Rescinded Breakthrough Status for Hep C Combo

Apr 09, 2015

Nasdaq

Merck has announced that its hepatitis C drugs -- grazoprevir and elbasvir -- have again been designated breakthrough therapies by the U.S. FDA.

In February, the drugmaker had reported that the FDA had rescinded the breakthrough designation for Merck's experimental hepatitis C treatment, because competing treatments with higher cure rates had been introducted by AbbVie and Gilead.

Merck's drug combo cured at least 90% of infected patients in a mid-stage clinical trials and Merck is testing them in late-stage studies, hoping to bring the new two-drug, single-pill combination to market. The new breakthrough designation covers only two small subpopulations -- patients infected with chronic HCV genotype 4, as well as hepatitis C patients with genotype 1 that have end-stage renal disease and are on hemodialysis

Read the Nasdaq release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments